Opioid-Maker Insys Wins Court Approval of Bankruptcy Plan
Insys Therapeutics Inc., the first drugmaker driven to bankruptcy by fallout from the opioid crisis, won court approval of a bankruptcy plan that pays less than a dime for each dollar it owes to the people, cities, states and tribes claiming damage from the drug epidemic, WSJ Pro Bankruptcy reported. Shareholders of the once-thriving company will be wiped out under the chapter 11 plan approved Thursday by Judge Kevin Gross in the U.S. Bankruptcy Court in Wilmington, Del. Insys filed for chapter 11 protection in June, after reaching a deal with the U.S. Justice Department and seeing a raft of its former leaders convicted on federal racketeering charges. In bankruptcy, the company sold the rights to its flagship opioid, a form of the fentanyl painkiller called Subsys, and other pharmaceutical assets. OxyContin maker Purdue Pharma LP filed for bankruptcy in September. It is in better financial shape than Insys, and Purdue’s owners, the Sackler family, have offered to contribute $3 billion to pay off creditors, including the same cities, states and tribes that sued Insys and others involved in the opioid crisis.
